Cognitive dysfunctions in depression - Underestimated symptom or new dimension?;Dysfunkcje poznawcze w depresji - Niedoszacowany objaw czy nowy wymiar?

Psychiatria Polska

Volumn 48, Issue 6, 2014, Pages 1105-1116

  Jarema, Marek ^a   Dudek, Dominika ^b   Czernikiewicz, Andrzej ^c  

^a Instytut Psychiatrii i Neurologii III Klinika Psychiatryczna Warszawa   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c Klinika Psychiatrii   (Poland)

Author keywords

Cognitive deficits; Depression; Vortioxetine

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VORTIOXETINE; PIPERAZINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SULFIDE;

AGE; ARTICLE; COGNITIVE DEFECT; DEPRESSION; DISEASE SEVERITY; EDUCATIONAL STATUS; EMOTION; GABAERGIC SYSTEM; HUMAN; COGNITION DISORDERS; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; DRUG EFFECTS;

COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PIPERAZINES; RECEPTORS, SEROTONIN; SEROTONIN RECEPTOR AGONISTS; SULFIDES;

EID: 84920163007     PISSN: 00332674     EISSN: 23915854     Source Type: Journal    
DOI: 10.12740/PP/31215     Document Type: Article

References (52)

1. Trivedi MH, Greer TL. Cognitive dysfunction in unipolar depression: implications for treatment. J. Affect Disord. 2014; 152: 19-27.
2. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006; 145: 39-48.
3. Etkin A, Gyurak A, O'Hara R. A neurobiological approach to the cognitive deficits of psychiatric disorders. Dialogues Clin. Neurosci. 2013; 15: 419-429.
4. Greer TL, Sunderajan P, Grannemann BD, Kurian BT, Trivedi MH. Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction? Depress. Res. Treat. 2014; DOI: 10.1155/2014/627863.
5. Naismith SL, Hickie JB, Turner K, Little CL, Winter V, Ward PB. i wsp. Neuropsychological performance in patients with depression is associated with clinical, etiological and genetic risk factors. J. Clin. Exp. Neuropsychol. 2003; 25: 866-877.
6. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, Guardia-Olmos J, Hinojosa-Calvo E, Herrera-Abarca JE. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J. Psychiatr. Res. 2009; 43: 855-863.
7. Murrough JW, Iacoviello B, Neumeister A, Charney DS, Iosifescu DV. Cognitive dysfunctions in depression: neurocircuitry and new therapeutic strategies. Neurobiol. Learn. Mem. 2011; 96: 553-563
8. Popiel A, Pragłowska E. Psychoterapia poznawczo-behawioralna. Teoria i praktyka. Warszawa: Wydawnictwo Paradygmat; 2008.
9. Beck AT. The evolution of the cognitive model of depression and its neurobiological correlates. Am. J. Psychiatry 2008; 165: 969-977.
10. Fennell MJV. Depression. W: Hawton K, Salkovskis PM, Kirk J, Clark DM. red. Cognitive behaviour therapy for psychiatric problems. Oxford: Oxford University Press, 1989. s. 169-234.
11. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol. Med. 2011; 41: 1165-1174.
12. Gorwood P. i wsp. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am. J. Psychiatry 2008; 165(6): 731-739.
13. Gotlib IH, Joormann J. Cognition and depression: current status and future directions. Ann. Rev. Clin. Psychol. 2010; 6: 285-312.
14. Bradley BP, Mogg K, Williams R. Implicit and explicit memory for emotion-congruent information in clinical depression and anxiety. Behav. Res. Therapy 1995; 33: 755-770.
15. Harmer CJ, O'Sullivan U, Favaron E, Massey-Chase R, Ayers R, Reinecke A. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am. J. Psychiatry 2009; 166: 1178-1184.
16. Murray LA, Whitehouse WG, Alloy LB. Mood congruence and depressive deficits in memory: A forced-recall analysis. Memory 1999; 7: 175-196.
17. Diagnostic and statistical manual of mental disorders. Fifth edition (DSM-5). Arlington, VA: American Psychiatric Association; 2013.
18. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
19. Lee RSC, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive deficits in first episode Major Depressive Disorder. J. Affect. Disord. 2012; 140: 113-124.
20. Clintock SM, Husain MM, Greer TL, Cullum CM. Association between depression severity and neurocognitive function in major depressive disorder: a review and synthesis. Neuropsychology 2010; 24: 9-34.
21. Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J. Affect. Disord. 2011; 134: 20-31.
22. Majer M, Ising M, Kunzel H, Binder EB, Holsboer F, Modell S. i wsp. Impaired divided attention predicts delayed response and risk of relapse in subjects with depressive disorders. Psychol. Med. 2004; 34: 1453-1463.
23. Alexopoulos GS, Meyers BS, Young RC, Kalyam B, Kakuma T, Gabrielle M. i wsp. Executive dysfunction and long-term outcomes of geriatric depression. Arch. Gen. Psychiatry 2000; 57: 285-290.
24. Gorwood P, Corruble E, Falissard B, Goodwin GM. Toxic effect of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am. J. Psychiatry 2008; 165: 731-739.
25. Post RM, Fleming J, Kapczinski F. Neurobiological correlates of illness progression in the recurrent affective disorders. J. Psychiatr. Res. 2012; 46: 561-573.
26. Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J. Neurol. Neurosurg. Psychiatry 2004; 75: 1662-1666.
27. Li G, Wang LY, Shofer JB, Thompson ML, Peskind ER, McCormick W. Temporal relationship between depression and dementia: finding from a large community-based 15-year follow-up study. Arch. Gen. Psychiatry 2011; 68: 970-977.
28. Butters MA, Young JB, Lopez O, Aizenstein HJ, Mulsant BH, Reynolds CF. i wsp. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin. Neurosci. 2008; 10: 345-357.
29. Iosifescu DV. Treating depression in the medically ill. Psychiatr. Clin. North Am. 2007; 30: 77-90.
30. Styron W. Ciemnos̈ć widoma. Esej o depresji. Warszawa: Wydawnictwo ͆wiat Ksiəżki; 2012.
31. Roiser JP, Sahakian B. Hot and cold cognition in depression. CNS Spectr. 2013; 18(3): 139-149.
32. Burt DB, Zembar MJ, Niederehe G. Depression and memory impairment: a meta-analysis of the association, its pattern, and specificity. Psychol. Bull. 1995; 117(2): 285-305.
33. Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. J. Affect. Disord. 2012; 140(2): 113-124.
34. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol. Med. 2013; 29: 1-12.
35. Erickson K, Drevets WC, Clark L, Cannon DM, Bain EE, Zarate CA Jr. i wsp. Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. Am. J. Psychiatry 2005; 162(11): 2171-2173.
36. Pimontel MA, Culang-Reinlieb ME, Morimoto SS, Sneed JR. Executive dysfunction and treatment response in late-life depression. Int. J. Geriatr. Psychiatry 2012; 27(9): 893-899.
37. Potter GG, Kittinger JD, Wagner HR, Steffens DC, Krishnan KR. Prefrontal neuropsychological predictors of treatment remission in late-life depression. Neuropsychopharmacol. 2004; 29(12): 2266-2271.
38. Irfan U, Khalid S. Relationship between cognitive impairment and depressive symptoms. J. Med. Sci. 2011; 4(3): 122-127.
39. Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression. Br. J. Psychiatry 2001; 178: 200-216.
40. Papazacharias A, Nardini M. The relationship between depression and cognitive deficits. Psychiatr. Danub. 2012; 24(supl. 1): 179-182.
41. Iverson GL, Lam RW. Rapid screening for perceived cognitive impairment in major depressive disorder. Ann. Clin. Psychiatry 2013; 25(2): 135-140.
42. Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr. Dis. Treat. 2014; 10: 349-354.
43. Russel J, Raskin J, Wiltse C, Walker D, Brawman-Mintzer O. Efficacy and tolerability of duloxetine treatment in elderly patients with major depressive disorder and concurrent anxiety symptoms. Psychiatry (Edgmont) 2007; 4(6): 33-45.
44. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetinereferenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int. Clin. Psychopharmacol. 2012; 27(4): 215-223.
45. Theunissen EL, Street D, Højer AM, Vermeeren A, van Oers A, Ramaekers JG. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin. Pharmacol. Therap. 2013; 93(6): 493-501.
46. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int. J. Neuropsychopharmacol. 2014; 17(10): 1557-1567.
47. Boulenger JP, Loft H, Florea A. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J. Psychopharmacol. 2012; 26(11): 1408-1416.
48. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebocontrolled, active reference study of Lu AA21004 in patients with major depressive disorder. Int. J. Neuropsychopharmacol. 2012; 15(5): 589-600.
49. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int. Clin. Psychopharmacol. 2014; 29(3): 138-149.
50. Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int. J. Neuropsychopharmacol. 2013; 16: 313-321.
51. Häggström L, Nielsen RZ, Danchenko N, Poulsen L. A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment. Eur. Neuropsychopharmacol. 2013; 23(supl. 2): S412.
52. McIntyre RS, Lophaven S, Olsen CK. Randomized, double-blind, placebo-controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). Neuropsychopharmacol. 2013; 38: S380-S381.